TickerTalks
Browse all tickers →
TickerTalks›$CRSP
CRCRSP

CRISPR Therapeutics AG

$CRSP·$4.8B·Biotechnology·Healthcare
$49.25-4.4%YTD-2.3%1Y-28.0%
Price updated 7h ago·X counts updated 5d ago
CRCRSP
$CRSPCRISPR Therapeutics AG
$49.25-4.41%341 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $CRSP on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

341X posts · last 7 days
Sep 29Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $CRSP's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-09-04

$CRSP (CRISPR Therapeutics) chatter is loudly bullish. CRSP presented positive Phase 1a data for CTX310 (in vivo CRISPR Cas9 gene editing therapy targeting ANGPTL3) at ESC Congress 2026 — 'deep and durable editing, triglyceride and LDL lowering.' 'Does the effect last? So far the answer looks encouraging' — one year after single infusion. TechBio/Genomics gene-editing 'cleanest basket of the three.' Bullish.

Read what X is saying about $CRSP

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $CRSP — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-10-03

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

A gene-editing name with in vivo Phase 1a data landing — the pipeline is where the thesis compounds or breaks.

CRISPR Therapeutics is one of the two public pure-play gene-editing companies, with a diversified pipeline across hematology, oncology, autoimmune, and now in vivo cardiovascular gene editing. The 2026 catalyst stack is thickening.

  • The business is still clinical-stage, which is the setup: Q2 revenue was $1.5M (growing 69% YoY off a tiny base) at a -8,933% operating margin — this is not an operating business, it's an R&D pipeline funded by cash on balance sheet, and the stock trades on data readouts.
  • The CTX310 Phase 1a readout at ESC Congress 2026 is specific and positive: deep and durable editing of ANGPTL3 with triglyceride and LDL lowering sustained a year after a single infusion — this is the first real validation of in vivo CRISPR with a one-shot cardiovascular target, which is the biggest TAM in the pipeline.

At 33% of its 52-week range with multiple catalysts stacked through the end of 2026 (per the news coverage), the setup is coiled on upcoming readouts. The ACR autoimmune zugo-cel data and additional CTX310 follow-up is what moves the stock next; a negative safety signal or any dilution surprise is the invalidation.

Agrees with X sentimentThe bullish CTX310 read is grounded in the Phase 1a data, and the 'cleanest basket' framing of gene editing within TechBio is a reasonable sector-level call. The one risk the thread doesn't flag is clinical-stage name volatility — sizing matters.

What to watch: Nov 9 Q3 earnings and the ACR autoimmune data readout — cash runway, pipeline updates, and any CTX310 follow-up data. Clean cash and multiple positive readouts is the trigger; a safety signal or dilution is the invalidation.

On the calendar: 2026-11-09 — Q3 earnings

event ahead 30dclinical catalysts

Read the AI verdict on $CRSP

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops CRISPR-Cas9 gene editing therapies, with Casgevy approved for sickle cell disease and beta-thalassemia.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $CRSP.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $CRSP

Neutral — Develops CRISPR-Cas9 gene editing therapies, with Casgevy approved for sickle cell disease and beta-thalassemia.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-8.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-21.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-134%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-8.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1218.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-30.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
-53.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 3, 2026$-0.94$-1.19+21.0%
Q1 2026May 4, 2026$-1.28$-1.19-7.6%
Q4 2025Feb 12, 2026$-1.37$-1.15-19.1%
Q3 2025Nov 10, 2025$-1.17$-1.26+7.1%
Next earningsMon, Nov 9·consensus EPS $-1.04

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$1.5M+68.6%-3346%-8933%$-1.28$-109.4M
Q4 FY25$864K-97.5%-6771%-17913%$-1.37$-93.1M
Q3 FY25$889K+47.7%-7177%-14855%$-1.17$-84.7M
Q2 FY25$892K+72.5%-5478%-14918%$-2.40$-114.0M

Forward consensus

5-year forecast · up to 13 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$36.7M$14.6M – $96.3M-$4.38-$5.51 – -$3.3213
FY27$147.4M$2.4M – $621.7M-$3.29-$4.92 – -$1.0713
FY28$560.0M$29.0M – $3.5B-$2.00-$7.26 – $9.8610
FY29$2.6B$166.0M – $13.1B$4.46-$0.97 – $27.465
FY30$6.8B$425.8M – $33.6B$19.34-$4.22 – $119.175

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.17%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-10.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-7.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 96.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.765-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellOct 14Simeon GeorgeDirector14.5K sh$720KSellOct 14Samarth KulkarniCEO4.1K sh$202KSellOct 14James R. KasingerGeneral Counsel and Secretary1.0K sh$51KSellOct 6James R. KasingerGeneral Counsel and Secretary2.0K sh$119KSellSep 22James R. KasingerGeneral Counsel and Secretary10.4K sh$626KSellSep 17Ali BehbahaniDirector13.7K sh$781KSellMay 29Naimish PatelChief Medical Officer3.8K sh$211K
+ 21 other (13 awards · 7 exempts · 1 gift) in window

See when $CRSP insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeJun 48-K — Item 5.02: Officer or director change · Item 5.03: Charter amendment · Item 5.07: Shareholder vote
AI summary

CRSP (CRSP) disclosed the results of its annual meeting of shareholders in an 8-K filing under Item 5.07. Shareholders voted on an equity incentive plan. All management-sponsored proposals were approved by majority shareholder vote. Annual meeting results are a routine disclosure that confirms shareholder ratification of the board's composition and compensation practices.

+ 13 other (5 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Knowzacks.com·9h agoCRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Knowzacks.com·4d agoHere is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stockzacks.com·5d agoCiti Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.fool.com·8d agoCRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026globenewswire.com·9d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPR

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport